
The first-of-its-kind AI-driven, non-blood-contact smart closed-loop diagnostic and treatment platform for heart conditions
Integrating physiological sensing, biomechanical support, and molecularly targeted intervention into a single implantable platform redefines the diagnosis, monitoring, and treatment of heart failure and structural heart disease
Hydraulic Tech
Hollow tubes filled with tailored liquids
Customised Design
Gentle pressure can massage the ventricles
Advanced Cardio Care
Naturally conforms to the surface of the heart, providing effective support
Our Story: From concept to platform with three-decade pursuit
Cambridge CardioMatrix Ltd founded in Cambridge, UK, is a medical technology company dedicated to research and development. The establishment of our company aims to commercialize Dr. Zhou Xiaohui's groundbreaking cardiac innovations. Dr. Zhou's work spans biomechanics, soft robotics, cardiology and biomedical engineering.
Our journey began with a simple yet profound question: Can we create a biomechanical interface that enables the heart to repair itself? With this question in mind, Dr Zhou started from the hand-woven prototype in the 1990s and, after three decades of unremitting pursuit, has gradually progressed to the current light-curing, 3D-printed smart platform. This continuous research and development process eventually has led to the creation of ASD technology and built a strong intellectual property portfolio including patents in China and the United States.


Minimally Invasive, Smart, Closed-loop Cardiac Monitoring, Diagnostic and Support Platforms
Advanced cardiac support solutions tailored to individual patient needs


Our mission is to create minimally invasive, smartt, closed-loop cardiac monitoring, diagnostic and support platforms to help address the rising global burden of cardiovascular disease.
Global Medical Need: The Cardiovascular Disease Crisis
523 million people worldwide are affected by cardiovascular diseases (CVDs)
20 million deaths occur annually — one-third of all global deaths
China: 290 million CVD patients while heart attacks and heart failure cases continue to rise
UK: 7.6 million CVD patients with 175,000 annual deaths
Despite progress made in stents, pharmaceuticals and ventricular assist devices (VADs), the current therapies still fail to effectively address the mechanical functional decline of failing hearts.
CardioMatrix offers a new bio-mechanical integrated solution to this unmet medical need.
Contact
Reach out for support or enquiries
Email:
Phone: +44 1223 981791
info@cardio-matrix.com
© 2025. Cambridge CardioMatrix, All rights reserved.
Find us at the heart of Cambridge, where innovation meets care in every beat
Cambridge CardioMatrix - MedTech International, Allia FBC, Kings Hedges Road, CB4 2HY Cambridge, UK
HOME ABOUT TECHNOLOGY DEVELOPMENT NEWS CONTACT US
